COVID-19
Excerpt from the Press Release: BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) — Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application…
Read More
Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it received acknowledgement by the Therapeutic Goods Administration (TGA) in Australia to conduct a Phase 1 clinical study of REVTx‑99…
Read More
Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it has been granted approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to conduct a Phase 1…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced a multi-year commitment to decreasing breast cancer screening disparities for Black women. The program is in partnership with the Black Women’s Health Imperative (BWHI), the only nonprofit organization created by Black…
Read More
Excerpt from the Press Release: BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced that a patient case report on the use of lenzilumab™ in critical COVID-19 was published online at OSF Preprints. The case report, titled “COVID-19 associated…
Read More
Excerpt from the Press Release: WAKEFIELD, MA – October 2, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that earlier this week the Company submitted a pre-IND meeting request to the FDA in advance of a planned study of Brilacidin, a defensin-mimetic drug candidate, for the treatment of…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–COVISTAT Inc. and its parent company Ensysce, received IND allowance and today initiated a Phase 1 clinical trial of oral nafamostat in healthy volunteers. Nafamostat, an ultra-potent protease inhibitor and an ingredient from Ensysce’s opioid overdose protection platform, is being developed as an oral treatment for COVID-19. The…
Read More
Excerpt from the Article: Researchers have reported hopeful results from an early clinical trial of a potential coronavirus vaccine developed by a team from from Beth Israel Deaconess Medical Center and Johnson & Johnson. The company announced earlier this week it has moved forward to field test what could be a the first single-shot vaccine for the virus in…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Diomics, a San Diego-based biotech company, today announced that it has been awarded a $2,125,000 Medical Technology Enterprise Consortium (MTEC) Other Transaction Agreement (OTA) with the U.S. Department of Defense to accelerate development and testing of its Diocheck™ SARS-CoV-2 Visual Immune Response Indicator, a transdermal skin patch that…
Read More
Excerpt from the Article: The company said at its R&D day that the Phase III COVE trial of mRNA-1273 had enrolled 25,296 of its planned 30,000 participants, while slightly more than 10,000 had received the first and second doses of the vaccine. One of the most closely watched Phase III Covid-19 vaccine trials is already…
Read More